Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up

Breast Cancer Research and Treatment

Volumn 137, Issue 3, 2013, Pages 883-892

  Zhang, Xuehong ^a   Tworoger, Shelley S ^a,b   Eliassen, A Heather ^a,b   Hankinson, Susan E ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Androgens; Breast cancer; Estrogens; Hormone receptor

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; PRASTERONE SULFATE; PROGESTERONE RECEPTOR; SEX HORMONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; BLOOD; BREAST TUMOR; MIDDLE AGED; RISK; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GONADAL STEROID HORMONES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RISK;

MLCS; MLOWN;

EID: 84877798650     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2391-z     Document Type: Article

References (46)

1. Hankinson SE, Eliassen AH (2007) Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk. J Steroid Biochem Mol Biol 106:24-30. doi: 10.1016/j.jsbmb.2007.05.012
2. Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones, Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606-616
3. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90:1292-1299. doi: 10.1093/jnci/90.17.1292
4. Adami HO, Persson I, Ekbom A, Wolk A, Ponten J, Trichopoulos D (1995) The aetiology and pathogenesis of human breast cancer. Mutat Res 333:29-35
5. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PHM, Biessy C, Dossus L, Lukanova A, Binghan S, Khaw KTG, Allen NE, Bueno-De-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12:1071-1082. doi: 10.1677/erc.1.01038
6. Bernstein L, Ross RK (1993) Endogenous hormones and breast cancer risk. Epidemiol Rev 15:48-65
7. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886. doi: 10.1093/jnci/81.24.1879
8. Rosner B, Colditz GA (1996) Nurses' health study: log-incidence mathematical model of breast cancer incidence. J Natl Cancer Inst 88:359-364. doi: 10.1093/jnci/88.6.359
9. Rosner B, Colditz GA, Iglehart JD, Hankinson SE (2008) Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses' Health Study. Breast Cancer Res 10:R55. doi: 10.1186/bcr2110
10. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of'the literature. Cancer Epidemiol Biomarkers Prev 13:1558-1568
11. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC (2012) Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 131:159-167. doi: 10.1007/s10549-011-1702-0
12. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96:218-228. doi: 10.1093/jnci/djh025
13. James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjonneland A, Olsen A, Overvad K, Mesrine S, Engel P, Clavel-Chapelon F, Chang-Claude J, Vrieling A, Boeing H, Schutze M, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Krogh V, Panico S, Tumino R, Sacerdote C, Rodriguez L, Buckland G, Sanchez MJ, Amiano P, Ardanaz E, Bueno-de-Mesquita B, Ros MM, van Gils CH, Peeters PH, Khaw KT, Wareham N, Key TJ, Allen NE, Romieu I, Siddiq A, Cox D, Riboli E, Kaaks R (2011) Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev Res (Phila) 4:1626-1635. doi: 10.1158/1940-6207.CAPR-11-0090
14. Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, Huang AJ, Vitolins M, Hubbell FA, Manson JE, Cochrane BB, Lane DS, Lee JS (2011) Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 103:562-570. doi: 10.1093/jnci/djr031
15. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96:1856-1865. doi: 10.1093/jnci/djh336
16. Kahan Z, Gardi J, Nyari T, Foldesi I, Hajnal-Papp R, Ormandi K, Lazar G, Thurzo L, Schally AV (2006) Elevated levels of circulating insulin-like growth factor-1, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study. Int J Oncol 29:193-200
17. Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauleys JA, Osteoporotic Fractures Res G (2005) Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomarkers Prev 14:1047-1051. doi: 10.1158/1055-9965.epi-04- 0375
18. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, Evangelista A, Allemani C, Micheli A, Tagliabue G, Schunemann HJ, Menard S, Berrino F, Muti P (2009) Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET Cohort. Cancer Epidemiol Biomarkers Prev 18:169-176. doi: 10.1158/1055-9965.epi-08-0808
19. Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, Morris HA, Tilley WD, Giles GG (2010) Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev 19:492-502. doi: 10.1158/1055-9965.epi-09-0532
20. Zeleniuchjacquotte A, Toniolo P, Levitz M, Shore RE, Koenig KL, Banerjee S, Strax P, Pasternack BS (1995) Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women. Cancer Epidemiol Biomarkers Prev 4:857-860
21. Belanger CF, Hennekens CH, Rosner B, Speizer FE (1978) The nurses' health study. Am J Nurs 78:1039-1040
22. Colditz GA, Hankinson SE (2005) The nurses' health study: lifestyle and health among women. Nat Rev Cancer 5:388-396. doi: 10.1038/nrc1608
23. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, Longcope C, Speizer FE (1995) Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87:1297-1302. doi: 10.1093/jnci/87.17.1297
24. Eliassen AH, Hankinson SE, Rosner B, Holmes MD, Willett WC (2010) Physical activity and risk of breast cancer among postmenopausal women. Arch Intern Med 170:1758-1764. doi: 10.1001/archinternmed.2010.363
25. Sodergard R, Backstrom T, Shanbhag V, Carstensen H (1982) Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem Mol Biol 16:801-810. doi: 10.1016/0022-4731(82)90038-3
26. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE (2004) Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64:6814-6819. doi: 10.1158/0008-5472.CAN-04-1870
27. Rosner B, Cook N, Portman R, Daniels S, Falkner B (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167:653-666. doi: 10.1093/aje/kwm348
28. Rosner B (1983) Percentage points for a generalized ESD many-outlier procedure. Technometrics 25:165-172. doi: 10.2307/1268549
29. Laird NM, Ware JH (1982) Random-effects models for longitudinal data. Biometrics 38:963-974. doi: 10.2307/2529876
30. Marshall RJ, Chisholm EM (1985) Hypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancer. Stat Med 4:337-344. doi: 10.1002/sim.4780040313
31. Miyoshi Y, Akazawa K, Kamigaki S, Ueda S, Yanagisawa T, Inoue T, Yamamura J, Taguchi T, Tamaki Y, Noguchi S (2004) Prognostic significance of intra-tumoral estradiol level in breast cancer patients. Cancer Lett 216:115-121. doi: 10.1016/j.canlet.2004.06.017
32. Horwitz KB, McGuire WL (1978) Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem 253:2223-2228
33. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270-282. doi: 10.1056/NEJMra050776
34. Dickson RB, Stancel GM (2000) Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr 135-145
35. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388. doi: 10.1093/jnci/90.18.1371
36. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18:1399-1411
37. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137. doi: 10.1056/NEJMoa062462
38. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed H, Howell A, Powles T, Clunie G, Collins R, Day N, Northover J, Investigators I (2002) First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 360:817-824
39. Brettes J-P, Mathelin C (2008) Dual effects of androgens on mammary gland. Bull Cancer 95:495-502. doi: 10.1684/bdc.2008.0631
40. Dimitrakakis C, Bondy C (2009) Androgens and the breast. Breast Cancer Res 11. doi: 10.1186/bcr2413
41. Liao DJ, Dickson RB (2002) Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 80:175-189. doi: 10.1016/s0960-0760(01)00185-6
42. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R, Toniolo P (2004) Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 90:153-159. doi: 10.1038/sj.bjc.6601517
43. Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA, Tamimi RM (2011) Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 17:1867-1874. doi: 10.1158/1078-0432.CCR-10-2021
44. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124:607-617. doi: 10.1007/s10549-010-0761-y
45. Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW, Lee KS (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 22:1755-1762. doi: 10.1093/annonc/mdq678
46. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938-1948. doi: 10.1056/NEJMra1001389